Ixmyelocel-T: Patient-specific Multicellular Therapy
Ixmyelocel-T is an investigational, patient-specific cell therapy in development at Aastrom for the treatment of severe, chronic cardiovascular diseases. It is derived from a patient's own bone marrow, which is collected by a physician and then processed at Aastrom. This short video explains this process and summarizes the latest clinical study of ixmyelocel-T in patients with critical limb ischemia.
For more information, visit aastrom.com/cell-therapy/product-overview/